SeQure Dx History
Founded in 2020, SeQure Dx is dedicated to advancing safety and precision in gene editing through its comprehensive suite of gene editing selection and risk assessment assays.
Our journey began with a mission to lower risk in cell therapy development and regulatory submission, ensuring safer therapies reach patients faster. To achieve this, we developed cutting-edge on-target and off-target assessment assays, providing unparalleled insights into genomic integrity. These innovations drive precision medicine forward, empowering safer, more effective therapeutic advancements.
A history of innovation driving safer cell and gene therapies
2013
Birth of CRISPR
First CRISPR-based gene editing companies are founded.
2013
First off-target publication
Fu, Y. et. al. “High-frequency off-target mutagenesis induced by CRISPR-cas nucleases in human cells ” published in Nature.
2014
GUIDE-Seq launch
GUIDE-seq developed in Keith Joung’s Lab to identify off-target editing.
2018
First CRISPR Clinical Trial
First CRISPR-based gene editing human clinical trial starts.
2020
Founding
SeQure Dx founded to identify and manage off-target risks for biopharma.
2022
New FDA Guidance
FDA published draft guidance “Human Gene Therapy Products Incorporating Human Genome Editing”.
2025
Joined MaxCyte
MaxCyte acquires SeQure Dx to enhance its best-in-class tools and services portfolio, reflecting its ongoing commitment to become a premier cell engineering solutions provider.
Learn more about our comprehensive suite of assays spanning from early discovery through pre-clinical and clinical development.
Have questions?
